Position: Head of the Chemotherapy Department at the N.N. Blokhin National Medical Research Center of Oncology.
Degree: DSc.
Education
In 2000, Dr. Fedenko graduated from the Second Medical Faculty of the I.M. Sechenov Moscow Medical Academy. Between 2000 and 2003, he trained at the general surgery residency program at the Russian Scientific Center of Surgery named after academician V.B. Petrovsky. Between 2003 and 2006, he was a PhD student at the Institute of Immunology of the Federal Medical-Biological Agency. In 2007, he successfully defended his PhD dissertation “Effect of some neuromodulators on the immune system and tolerability of adjuvant chemoradiotherapy in patients with breast cancer”. In 2016, he defended his DSc dissertation “Strategy of drug treatment of soft tissue sarcomas”.
Dr. Fedenko has completed several advanced training courses at the MD Anderson Cancer Center and University of Southern California.
Professional experience
Since 2007, Dr. Fedenko has worked as an oncologist at the Chemotherapy Department of the N.N. Blokhin National Medical Research Center of Oncology. Between 2010 and 2017, he was a senior researcher at the same department. Since 2017, he serves as the head of the Chemotherapy Department.
Scientific interests
Dr. Fedenko has experience and knowledge of drug treatment of most solid tumors. He places special focus on drug treatment of rare (orphan) oncological diseases.
Publications
Dr. Fedenko has authored more than 78 scientific articles in Russian and English. He actively participates in scientific symposiums in Russia and abroad.
Membership in professional medical organizations
Dr. Fedenko serves as the executive director of the East European Sarcoma Group (EESG), is an expert on sarcoma and GIST treatment of the European Society for Medical Oncology (ESMO), Russian Society of Clinical Oncology (RUSSCO). He supervises RUSSCO work groups on development of clinical guidelines on sarcomas of bones and soft tissues. He is also a member of the American Society of Clinical Oncology (ASCO) and Connective Tissue Oncology Society (CTOS).
